Skip to main content
Erschienen in: Medical Oncology 4/2014

01.04.2014 | Original Paper

Expression of PTEN and mTOR in sacral chordoma and association with poor prognosis

verfasst von: Kangwu Chen, Jianqiang Mo, Ming Zhou, Genlin Wang, Guizhong Wu, Hao Chen, Kai Zhang, Huilin Yang

Erschienen in: Medical Oncology | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

Sacral chordoma is an aggressive, locally invasive neoplasm, and has a poor prognosis. However, the molecular basis for the clinical behavior remains unknown. The purpose of this study was to investigate the expression of phosphatase and tensin homolog deleted on chromosome 10 (PTEN) and mammalian target of rapamycin (mTOR) in sacral chordoma, and explore their roles in the prognosis. PTEN and mTOR were detected immunohistochemically in 40 sacral chordoma tissues and 10 adjacent normal tissues. Correlations between PTEN and mTOR expression and clinicopathological factors were analyzed. Kaplan–Meier survival curves and log-rank test were used to analyze the continuous disease-free survival time (CDFS). The expression of PTEN in sacral chordoma was significantly lower than that in adjacent normal tissues, while the levels of mTOR expression in sacral chordoma were significantly higher than that in adjacent normal tissues (P = 0.000, P = 0.030). The positive expression of mTOR appears to correlate with the negative expression of PTEN in sacral chordoma (P = 0.021). PTEN-negative expression and mTOR-positive expression were associated with tumor invasion into the surrounding muscles (P = 0.038, P = 0.014). Log-rank test showed that PTEN-negative and mTOR-positive expressions had an important impact on the patients’ CDFS (P = 0.011, P = 0.015). Our results suggest that PTEN and mTOR might play an important role in the local invasiveness of sacral chordoma. PTEN and mTOR might be recognized as important prognostic predictors of recurrence and could be used as potential therapeutic targets for the treatment for sacral chordoma.
Literatur
1.
Zurück zum Zitat Casali PG, Stacchiotti S, Sangalli C, Olmi P, Gronchi A. Chordoma. Curr Opin Oncol. 2007;19:367–70.PubMedCrossRef Casali PG, Stacchiotti S, Sangalli C, Olmi P, Gronchi A. Chordoma. Curr Opin Oncol. 2007;19:367–70.PubMedCrossRef
2.
Zurück zum Zitat Fuchs B, Dickey ID, Yaszemski MJ, Inwards CY, Sim FH. Operative management of sacral chordoma. J Bone Joint Surg Am. 2005;87:2211–6.PubMedCrossRef Fuchs B, Dickey ID, Yaszemski MJ, Inwards CY, Sim FH. Operative management of sacral chordoma. J Bone Joint Surg Am. 2005;87:2211–6.PubMedCrossRef
3.
Zurück zum Zitat Chugh R, Tawbi H, Lucas DR, Biermann JS, Schuetze SM, Baker LH. Chordoma: the nonsarcoma primary bone tumor. Oncologist. 2007;12:1344–50.PubMedCrossRef Chugh R, Tawbi H, Lucas DR, Biermann JS, Schuetze SM, Baker LH. Chordoma: the nonsarcoma primary bone tumor. Oncologist. 2007;12:1344–50.PubMedCrossRef
4.
Zurück zum Zitat Pal SK, Figlin RA, Reckamp KL. The role of targeting mammalian target of rapamycin in lung cancer. Clin Lung Cancer. 2008;9:340–5.PubMedCrossRef Pal SK, Figlin RA, Reckamp KL. The role of targeting mammalian target of rapamycin in lung cancer. Clin Lung Cancer. 2008;9:340–5.PubMedCrossRef
5.
Zurück zum Zitat Contreras AG, Dormond O, Edelbauer M, Calzadilla K, Hoerning A, Pal S, Briscoe DM. mTOR-understanding the clinical effects. Transplant Proc. 2008;40:S9–12.PubMedCentralPubMedCrossRef Contreras AG, Dormond O, Edelbauer M, Calzadilla K, Hoerning A, Pal S, Briscoe DM. mTOR-understanding the clinical effects. Transplant Proc. 2008;40:S9–12.PubMedCentralPubMedCrossRef
6.
Zurück zum Zitat McBride SM, Perez DA, Polley MY, et al. Activation of PI3 K/mTOR pathway occurs in most adult low-grade gliomas and predicts patient survival. J Neurooncol. 2010;97:33–40.PubMedCentralPubMedCrossRef McBride SM, Perez DA, Polley MY, et al. Activation of PI3 K/mTOR pathway occurs in most adult low-grade gliomas and predicts patient survival. J Neurooncol. 2010;97:33–40.PubMedCentralPubMedCrossRef
7.
Zurück zum Zitat Han W, Ming M, He TC, He YY. Immunosuppressive cyclospor in Aactivates AKT in keratinocytes through PTEN suppression: implications in skin carcinogenesis. J Biol Chem. 2010;285:11369–77.PubMedCentralPubMedCrossRef Han W, Ming M, He TC, He YY. Immunosuppressive cyclospor in Aactivates AKT in keratinocytes through PTEN suppression: implications in skin carcinogenesis. J Biol Chem. 2010;285:11369–77.PubMedCentralPubMedCrossRef
8.
Zurück zum Zitat Chen KW, Yang HL, Lu J, Liu JY, Chen XQ. Prognostic factors of sacral chordoma after surgical therapy: a study of 36 patients. Spinal Cord. 2010;48:166–71.PubMedCrossRef Chen KW, Yang HL, Lu J, Liu JY, Chen XQ. Prognostic factors of sacral chordoma after surgical therapy: a study of 36 patients. Spinal Cord. 2010;48:166–71.PubMedCrossRef
9.
Zurück zum Zitat Chen KW, Yang HL, Lu J, et al. Expression of vascular endothelial growth factor and matrix metalloproteinase-9 in sacral chordoma. J Neurooncol. 2011;101:357–63.PubMedCrossRef Chen KW, Yang HL, Lu J, et al. Expression of vascular endothelial growth factor and matrix metalloproteinase-9 in sacral chordoma. J Neurooncol. 2011;101:357–63.PubMedCrossRef
10.
Zurück zum Zitat Chen C, Yang HL, Chen KW, et al. High expression of survivin in sacral chordoma. Med Oncol. 2013;30:529.PubMedCrossRef Chen C, Yang HL, Chen KW, et al. High expression of survivin in sacral chordoma. Med Oncol. 2013;30:529.PubMedCrossRef
11.
Zurück zum Zitat Rosner M, Hanneder M, Siegel N, Valli A, Fuchs C, Hengstschlager M. The mTOR pathway and its role in human genetic diseases. Mutat Res. 2008;659:284–92.PubMedCrossRef Rosner M, Hanneder M, Siegel N, Valli A, Fuchs C, Hengstschlager M. The mTOR pathway and its role in human genetic diseases. Mutat Res. 2008;659:284–92.PubMedCrossRef
12.
Zurück zum Zitat Scheper MA, Chaisuparat R, Nikitakis NG, Sauk JJ. Expression and alterations of the PTEN/AKT/mTOR pathway in ameloblastomas. Oral Dis. 2008;14:561–8.PubMedCrossRef Scheper MA, Chaisuparat R, Nikitakis NG, Sauk JJ. Expression and alterations of the PTEN/AKT/mTOR pathway in ameloblastomas. Oral Dis. 2008;14:561–8.PubMedCrossRef
13.
Zurück zum Zitat Presneau N, Shalaby A, Idowu B, et al. Potential therapeutic targets for chordoma: PI3 K/AKT/TSC1/TSC2/mTOR pathway. Br J Cancer. 2009;100:1406–14.PubMedCentralPubMedCrossRef Presneau N, Shalaby A, Idowu B, et al. Potential therapeutic targets for chordoma: PI3 K/AKT/TSC1/TSC2/mTOR pathway. Br J Cancer. 2009;100:1406–14.PubMedCentralPubMedCrossRef
14.
Zurück zum Zitat Schwab J, Antonescu C, Boland P, et al. Combination of PI3 K/mTOR inhibition demonstrates efficacy in human chordoma. Anticancer Res. 2009;29:1867–71.PubMed Schwab J, Antonescu C, Boland P, et al. Combination of PI3 K/mTOR inhibition demonstrates efficacy in human chordoma. Anticancer Res. 2009;29:1867–71.PubMed
15.
16.
Zurück zum Zitat Li J, Yen C, Liaw D, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 1997;275:1943–7.PubMedCrossRef Li J, Yen C, Liaw D, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 1997;275:1943–7.PubMedCrossRef
17.
Zurück zum Zitat Risinger JI, Hayes AK, Berchuck A, Barrett JC. PTEN/MMAC1 mutations in endometrial cancers. Cancer Res. 1997;57:4736–8.PubMed Risinger JI, Hayes AK, Berchuck A, Barrett JC. PTEN/MMAC1 mutations in endometrial cancers. Cancer Res. 1997;57:4736–8.PubMed
18.
Zurück zum Zitat Bakarakos P, Theohari I, Nomikos A, Mylona E, et al. Immunohistochemical study of PTEN and phosphorylated mTOR proteins in familial and sporadic invasive breastcarcinomas. Histopathology. 2010;56:876–82.PubMedCrossRef Bakarakos P, Theohari I, Nomikos A, Mylona E, et al. Immunohistochemical study of PTEN and phosphorylated mTOR proteins in familial and sporadic invasive breastcarcinomas. Histopathology. 2010;56:876–82.PubMedCrossRef
19.
Zurück zum Zitat Cheng ZY, Guo XL, Yang XY, et al. PTEN and rapamycin inhibiting the growth of K562 cells through regulating mTOR signaling pathway. J Exp Clin Cancer Res. 2008;27:87.PubMedCentralPubMedCrossRef Cheng ZY, Guo XL, Yang XY, et al. PTEN and rapamycin inhibiting the growth of K562 cells through regulating mTOR signaling pathway. J Exp Clin Cancer Res. 2008;27:87.PubMedCentralPubMedCrossRef
20.
Zurück zum Zitat Han S, Polizzano C, Nielsen GP, Hornicek FJ, Rosenberg AE, Ramesh V. Aberrant hyperactivation of akt and mammalian target of rapamycin complex 1 signaling in sporadic chordomas. Clin Cancer Res. 2009;15:1940–6.PubMedCentralPubMedCrossRef Han S, Polizzano C, Nielsen GP, Hornicek FJ, Rosenberg AE, Ramesh V. Aberrant hyperactivation of akt and mammalian target of rapamycin complex 1 signaling in sporadic chordomas. Clin Cancer Res. 2009;15:1940–6.PubMedCentralPubMedCrossRef
21.
Zurück zum Zitat Wang L, Yue W, Zhang L, Zhao X, Wang Y, Xu S. mTOR and PTEN expression in non-small cell lung cancer: analysis by real-time fluorescence quantitative polymerase chain reaction and immunohistochemistry. Surg Today. 2012;42:419–25.PubMedCrossRef Wang L, Yue W, Zhang L, Zhao X, Wang Y, Xu S. mTOR and PTEN expression in non-small cell lung cancer: analysis by real-time fluorescence quantitative polymerase chain reaction and immunohistochemistry. Surg Today. 2012;42:419–25.PubMedCrossRef
Metadaten
Titel
Expression of PTEN and mTOR in sacral chordoma and association with poor prognosis
verfasst von
Kangwu Chen
Jianqiang Mo
Ming Zhou
Genlin Wang
Guizhong Wu
Hao Chen
Kai Zhang
Huilin Yang
Publikationsdatum
01.04.2014
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 4/2014
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-014-0886-7

Weitere Artikel der Ausgabe 4/2014

Medical Oncology 4/2014 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.